丹玄口康治疗口腔黏膜下纤维化的临床研究

Clinical Research of Danxuan Koukang on Treatment of Oral Submucous Fibrosis

目的探讨丹玄口康治疗口腔黏膜下纤维化(OSF)的临床疗效机制。方法将确诊为OSF的62例患者随机分为两组,治疗组32例,对照组30例,分别给予丹玄口康(DXKK)和雷公藤多甙(LGTDD)口服,观察两种药物的临床疗效及其对外周血T淋巴细胞亚群、血液流变学的影响。结果DXKK治疗OSF临床疗效明显优于LGTDD(P<0.01);T淋巴细胞亚群CD4+、CD4+/CD8+明显降低(P<0.01或P<0.05);全血黏度、血浆黏度、红细胞聚集指数等血液流变学各项指标均有明显改善(P<0.01或P<0.05)。结论DXKK治疗OSF安全有效,并能显著改善微循环,调节局部免疫。

Objective To investigate the therapeutic mechanism of Danxuan Koukang （DXKK） on oral submucous fibrosis （OSF）. Methods 62 patients with OSF were randomly divided into two groups in which 32 cases in experimental group were treated with DXKK and 30 cases in control group with Leigongteng Duodai lymphocytes and hemorrheology （LGTDD） orally. The therapeutic effects, changes of subgroup of T indexes were observed. Results The curative effect of DXKK was much more than that of LGTDD （P〈0.01）; CD4^＋, CD4^＋/CD8^＋ of T lymphocytes were significantly decreased （P〈0.01 or P〈0.05）; and each index of hemorrheology was significantly improved （P〈0.01 or P〈0.05）. Conclusions DXKK is effective and safe for the treatment of OSF, which indicates that DXKK can significantly improves microcirculation and regulate local immunity.